|
|
HALO® Breast Pap Test Backgrounder
The HALO® Breast Pap Test is FDA cleared for the collection of nipple aspirate fluid (NAF) for cytological evaluation. The collected fluid can be used in the determination and/or differentiation of normal versus pre-malignant versus malignant cells.
The HALO System is a simple, reliable method for NAF collection. NAF analysis is an objective assessment of a patient's breast health and can detect early warning signs of ductal cellular changes. Regular assessment and tracking of cellular changes in the milk ducts, where most breast cancer begins, enables clinicians and patients to take control of breast health.
HALO is not a diagnostic test and it cannot be used to exclude breast cancer. Patients should continue to undergo other clinical breast screening procedures (mammography, clinical breast examination, self breast examination) as determined by and with their physicians.
Incorporating Halo into routine practice will enable physicians and patients to monitor cellular changes within breast ducts earlier, before they develop into larger, potentially cancerous lesions.
HALO is noninvasive, objective and repeatable, plus it's quick - just five minutes. Routine assessment with HALO will enable breast health monitoring and the ability to react to cellular changes early.
About NeoMatrix
Based in Irvine, Calif., NeoMatrix develops innovative devices that allow women and their doctors to promote optimal breast health. The company’s premier product, the HALO Breast Pap test, is the only fully automated noninvasive breast cancer risk assessment device designed for use in the primary care setting as part of an annual well-woman visit.